Arthur Kirsch Net Worth

The estimated Net Worth of Arthur S Kirsch is at least 605 千$ dollars as of 10 November 2021. Mr. Kirsch owns over 30,000 units of Kadmon Inc stock worth over 304,000$ and over the last 9 years he sold KDMN stock worth over 0$. In addition, he makes 301,250$ as Independent Director at Kadmon Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Kirsch KDMN stock SEC Form 4 insiders trading

Arthur has made over 8 trades of the Kadmon Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he bought 30,000 units of KDMN stock worth 127,200$ on 10 November 2021.

The largest trade he's ever made was buying 50,000 units of Kadmon Inc stock on 8 December 2017 worth over 73,500$. On average, Arthur trades about 8,442 units every 77 days since 2015. As of 10 November 2021 he still owns at least 32,000 units of Kadmon Inc stock.

You can see the complete history of Mr. Kirsch stock trades at the bottom of the page.

Arthur Kirsch biography

Arthur S. Kirsch serves as Independent Director of the Company. Mr. Kirsch previously served as Senior Advisor and Head of Healthcare at GCA Global, an investment bank providing strategic M&A, capital markets and private funds advisory services to growth companies and market leaders. From 1994 to 2004, Mr. Kirsch was Global Head of Healthcare Research, with more than 200 companies under coverage, and later served as Head of Capital Markets at Vector Securities, a healthcare investment banking boutique that was later acquired by Prudential Securities. From 1990 to 1993, Mr. Kirsch was Chief Executive Officer of NatWest Markets, currently the investment banking arm of The Royal Bank of Scotland Group. Mr. Kirsch began his career on Wall Street at Drexel Burnham Lambert, where he served as Executive Vice President of the Global Equity Division and as a member of the Executive Committee. Mr. Kirsch serves on the Board of Directors of Liquidia Technologies, Inc., a public nanotechnology healthcare company, where he is also Chair of the Audit Committee. Mr. Kirsch previously served on the Board of Directors of Immunomedics, a public biopharmaceutical company, where he also served on the Audit Committee. Mr. Kirsch also previously served as Chairman of the Board of Directors at Aralez, Inc. a publicly traded biopharmaceutical company, where he was also Chair of the Audit Committee. Mr. Kirsch received his B.A. in Finance from the University of Rhode Island and his MBA in Finance from Bernard M. Baruch College.

What is the salary of Arthur Kirsch?

As the Independent Director of Kadmon Inc, the total compensation of Arthur Kirsch at Kadmon Inc is 301,250$. There are 5 executives at Kadmon Inc getting paid more, with Harlan Waksal having the highest compensation of 4,742,770$.

How old is Arthur Kirsch?

Arthur Kirsch is 68, he's been the Independent Director of Kadmon Inc since 2019. There are 2 older and 8 younger executives at Kadmon Inc. The oldest executive at Kadmon Holdings Inc is Eugene Bauer, 77, who is the Independent Director.

What's Arthur Kirsch's mailing address?

Arthur's mailing address filed with the SEC is 419 DAVIS DRIVE,, SUITE 100, MORRISVILLE, NC, 27560.

Insiders trading at Kadmon Inc

Over the last 8 years, insiders at Kadmon Inc have traded over 7,020,661$ worth of Kadmon Inc stock and bought 7,084,916 units worth 54,943,934$ . The most active insiders traders include Advisors Llcperceptive Life...、Asset Management Lp Golden ...、Daniel S Third Point Llc Loeb. On average, Kadmon Inc executives and independent directors trade stock every 29 days with the average trade being worth of 1,948,175$. The most recent stock trade was executed by Harlan Waksal on 13 March 2020, trading 16,000 units of KDMN stock currently worth 46,880$.

What does Kadmon Inc do?

Kadmon is a clinical-stage biopharmaceutical company that discovers, develops and delivers transformative therapies for unmet medical needs. Its clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies.

Complete history of Mr. Kirsch stock trades at Immunomedics、Kadmon Inc、Liquidia Corp

Kadmon Inc executives and stock owners

Kadmon Inc executives and other stock owners filed with the SEC include:

• Harlan Waksal,
  President, Chief Executive Officer, Director
• Steven Meehan,
  Chief Financial Officer, Executive Vice President
• Gregory Moss,
  Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
• Dr. Harlan W. Waksal,
  Pres, CEO & Director
• Gregory S. Moss Esq.,
  Exec. VP, Gen. Counsel, Corp. Sec. & Chief Compliance Officer
• Arthur Kirsch,
  Independent Director
• David Cohen,
  Independent Director
• Cynthia Schwalm,
  Independent Director
• Eugene Bauer,
  Independent Director
• Tasos Konidaris,
  Non-Executive Independent Chairman of the Board
• Ellen Cavaleri,
  IR Contact Officer
• Nancy Miller-Rich,
  Director
• John Ryan,
  Executive Vice President, Chief Medical Officer
• Dr. Simon Cooper,
  Sr. VP & Chief Medical Officer
• Haya Taitel M.S., R.Ph.,
  Sr. VP & Chief Commercial Officer
• Sanjay Aggarwal,
  Sr. VP of Clinical Devel.
• Kyle Carver,
  Sr. VP, Chief Accounting Officer & Controller
• Charles Darder,
  Principle Accounting Officer
• Asset Management Lp Golden ...,
  
• D. Dixon Boardman,
  
• Konstantin Poukalov,
  EVP, Chief Financial Officer
• Alexandria Forbes,
  
• Andrew B Cohen,
  
• I, Llc Kadmon,
  
• Susan Wiviott,
  
• Shengda Zan,
  
• Thomas E Shenk,
  
• Steven N. Gordon,
  Exec VP, GC, Chief Admin, Comp
• Lawrence Kenneth Cohen,
  Exec. VP, Business Develop.
• Daniel S Third Point Llc Loeb,
  
• Bart M Schwartz,
  
• Advisors Llcperceptive Life...,
  
• Kyle Carver,
  SVP, CAO, Controller
• Cynthia Louise Flowers,
  Director